Cite
HARVARD Citation
Freyer, C. et al. (2023). Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement. Expert review of anticancer therapy. 23 (4), pp. 351-359. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Freyer, C. et al. (2023). Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement. Expert review of anticancer therapy. 23 (4), pp. 351-359. [Online].